Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 8;229(Supplement_3):S342-S349.
doi: 10.1093/infdis/jiad463.

Molecular Point-of-Care Testing for Hepatitis C: Available Technologies, Pipeline, and Promising Future Directions

Elena Ivanova Reipold  1 , Sonjelle Shilton  1 , Marco Donolato  1 , Marta Fernandez Suarez  1
Affiliations
Review

Molecular Point-of-Care Testing for Hepatitis C: Available Technologies, Pipeline, and Promising Future Directions

Elena Ivanova Reipold et al. J Infect Dis. .

Abstract

Hepatitis C virus (HCV) remains a major public health problem, despite the availability of effective treatments. In many areas, the ability to diagnose HCV infection at the point of care is key to scaling up access to care and treatment. To achieve this, an accurate, easy-to-use, and affordable diagnostic tool is required-this would enable decentralized testing and the creation of one-stop centers to eliminate gaps in the care cascade, which would help reach the millions of people with undiagnosed HCV infection in low- and middle-income countries and high-risk populations in high-income countries. In this review, we examine the current state of point-of-care molecular technologies, the advantages and limitations of currently available devices (both near- and true-point-of-care), the potential of molecular testing to transform diagnostic medicine in the future, and the challenges that need to be addressed for broader adoption of this technology in routine clinical practice.

Keywords: diagnostics; hepatitis C; molecular assays; point-of-care.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. FIND had joint collaborative projects with Cepheid, Molbio, PlusLife, and Sherlock Biosciences and provided financial support to these companies. No financial support from these companies was receieved by FIND or any of the authors. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Types of point-of-care (POC) technologies.
See this image and copyright information in PMC

References

    1. Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021; 45:101596. - PubMed
    1. World Health Organization . Global health sector strategy on viral hepatitis 2016–2021,2016.https://www.emcdda.europa.eu/system/files/attachments/9478/WHO-HIV-2016..... Accessed 1 March 2023.
    1. World Health Organization . Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Web annex 1: Key data at a glance,2021.http://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.... Accessed 28 February 2023.
    1. World Health Organization . Update recommendations on simplified service delivery and diagnostics for hepatitis C infection,2022.https://www.who.int/publications/i/item/9789240052697. Accessed 28 February 2023.
    1. Reipold EI, Trianni A, Krakower D, et al. . Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. BMC Infect Dis 2017; 17(Suppl 1):702. - PMC - PubMed

Publication types

MeSH terms